← ANALYST RATINGS · TIPRANKS
Organogenesis Holdings (ORGO): analyst forecast and price target
Analyst consensus
0 Buy0 Hold0 Sell
Ratings of 0 analysts in the last 3 months · top analysts only12-month forecast
Based on 0 price targets given in the last 3 months, the average target is —, the highest —, the lowest —. The average is — from the last price of $1.00.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $1.00 → $0.99−1.1% | Hold | −1.0% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $1.00 → $0.95−4.6% | Hold | −4.5% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $1.00 → $0.99−1.1% | Hold | −1.0% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $1.00 → $0.95−5.1% | Sell | −5.0% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $1.00 → $0.96−4.1% | Hold | −4.0% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $1.00 → $0.97−3.3% | Hold | −3.2% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| Ravi Misra★★★★★★★★★★#11202 · hits 35% · avg −10.7% | Truist Financial | $2.00 | Hold | +100.2% | Reiterated | 11.08.26on TipRanks Aug 12 22:25 | +1.9%next day −4.5% · 5 days −4.9% | ↗ |
| Ryan Zimmerman★★★★★★★★★★#3375 · hits 46% · avg +3.3% | BTIG | — | Hold | — | Reiterated | 07.08.26on TipRanks 08:01 | −23.4%next day 0.0% · 5 days −4.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Organogenesis Holdings
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $2.00 at a price of $1.37 (+46.0%); now: $2.00 at $1.00 (+100.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.17 (from $-0.18 to $-0.17). Last quarter: $-0.71.
Sales
Next quarter’s sales estimate — $52M (from $52M to $53M). Last quarter: $44M.
Best top-analyst consensus in the sector · Healthcare
About Organogenesis Holdings
- CEO: Gary S. Gillheeney
- Employees: 854
- 85 Dan Road, Canton, MA, 02021, US
- organogenesis.com
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Ca
Data from the stock’s TipRanks forecast page, read 150 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗